BioSpace News Archive

Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced the European Patent Office granted the Company’s patent for a method of treating Alzheimer’s disease in humans by administering its lead compound, ANVS401.

Sensor Electronic Technology, Inc., the World’s first compound semiconductor for UV LED solutions and Seoul Viosys ’ subsidiary, announced that it launches portable air purifiers of brand “VAC” and surface disinfection devices of brand “VSM+” with Violeds technology to reduce infection from various harmful bacteria including new coronavirus.

Innovative platform includes an AI-enabled engagement tool to personalize the online pharmacy experience.

Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted two new employees a non-qualified stock option to purchase an aggregate of 15,200 shares of Calithera’s common stock, at a per share exercise price of $5.82, the closing trading price on May 29, 2020.

Program will fund 11 unique solutions for challenges posed by COVID-19 from Canadians across the country

BION-1301 was well-tolerated, with no serious adverse events (SAEs), treatment discontinuations or events meeting stopping criteria, across a wide range of doses Pharmacokinetics (PK) of BION-1301 were generally dose-proportional with an estimated half-life of 33 days, suggesting the potential for monthly dosing BION-1301 dose-dependently and durably reduced IgA and IgM, and to a lesser extent, IgG, providing a pharmacodynamic (PD) window to potentially exploit reductions in IgA while

Research includes innovations in mRNA and protein engineering and delivery science to improve therapeutic properties Highlights research results from ongoing collaborations with International AIDS Vaccine Initiative (IAVI), National Institute of Allergy and Infectious Diseases (NIAID) and Bill & Melinda Gates Foundation toward development of an HIV vaccine CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage

IVERIC bio, Inc. reported that on June 1, 2020, the Company granted non-statutory stock options to purchase an aggregate of 34,000 shares of the Company’s common stock to two newly hired, non-executive employees.

Tenax Therapeutics Reports Positive Results from Phase 2 Trial of Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - Demonstrated a significant reduction in right atrial and pulmonary capillary wedge pressures - Demonstrated a significant improvement with 6-minute walk distance - No significant safety issues. - Management to host conference call and webcast today at

Global Blood Therapeutics, Inc. announced that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast on Tuesday, June 9, 2020, at 3:50 p.m. Eastern Time.